Drug: CTL019 (Novartis)
Status: Granted breakthrough therapy designation for the treatment of adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) who have failed two or more prior therapies
Significant Information:
- Investigational chimeric antigen receptor T-cell therapy
- Based on data from the Phase II JULIET study, which is evaluating the efficacy and safety of CTL019 in adult patients with r/r DLBCL
- CTL019 also has received this designation for the treatment of r/r